Posts Archive

BOSTON Study This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and...

NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple...

Multiple Myeloma Research Consortium NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous...

NCT03309111: Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Study of ISB 1342, a...

KarMMa bb2121 NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma...

Modakafusp alfa (Formerly TAK-573) NCT03215030: Phase 1/2: A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics,...

MASTER TRIAL Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER) Dara-KRd Monoclonal...

The GRIFFIN trial Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and...

Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma This phase II trial studies how well isatuximab works in...

NCT02659293: Phase 3: ATLAS Trial: Carfilzomib, Lenalidomide and Dex Vs Lenalidomide Alone After ASCT KRd Vs R NDMM Trial of Carfilzomib,...

TOURMALINE-MM1 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and...

Bellini RRMM A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as...

NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors NCT02663518: Phase 1: A...

HORIZON A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients...

NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation NCT02671448: Pilot Trial of Homebound Stem Cell Transplantation In this...

CC-220-MM-001 NDMM Newly Diagnosed Multiple Myeloma RRMM Relapsed Refractory Multiple Myeloma A Study to Determine Dose, Safety,...

NCT02863991: Phase 1/2: Oral ONC201 in Relapsed/Refractory Multiple Myeloma ONC201 is an orally bioavailable first-in-class small...

NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory...

RRMM Relapsed Refractory Multiple Myeloma NCT02649790: Phase 1/2: Study of the Safety, Tolerability and Efficacy of KPT-8602 in...